Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06632236
Title 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD)
Acronym 5G-EMERALD
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Institute of Cancer Research, United Kingdom
Indications
Therapies
Age Groups: child | senior | adult
Covered Countries GBR


No variant requirements are available.